If most of the drug is gone, you may experience side effects if you resume the medicine at your regular dose
Health markers improve in bloodwork
Regulatory environment supports continued innovation in obesity treatment with streamlined approval pathways for novel GLP-1 formulations
During the item generation and discussion and clarification phases, the experts identified 14 distinct challenges: costs, supply challenges, lack of evidence, polypharmacy, barriers to prescription, lack of knowledge, adherence concerns, aversion to injection therapy, clinical inertia, titration needs, perceived health state, fear of adverse effects, lack of clinical guideline recommendations, and lack of measurable outcomes to guide therapy